4.5 Review

WONOEP appraisal: Imaging biomarkers in epilepsy

期刊

EPILEPSIA
卷 58, 期 3, 页码 315-330

出版社

WILEY
DOI: 10.1111/epi.13621

关键词

Biomarker; Epileptogenesis; Traumatic brain injury; Imaging; Inflammation; Blood-brain barrier

资金

  1. Neurobiology Commission of the International League Against Epilepsy
  2. Harinarayan Family Foundation
  3. Cyberonics Inc. (U.S.A.)
  4. Insys Therapeutics Inc. (U.S.A.)
  5. Astellas Pharma (Japan)
  6. Meiji Seika Pharma (Japan)
  7. European Union's Seventh Framework Programme (FP7) [602102]
  8. Dutch Epilepsy Foundation [16-05]
  9. BOF UAntwerpen
  10. Research Foundation Flanders (FWO) [1.5.110.14N, G.038515N, G.A009.13N]
  11. Queen Elisabeth Medical Foundation for Neurosciences
  12. European Union's Horizon research and innovation programme under the Marie Sklodowska-Curie grant [642881]
  13. Deutsche Forschungsgemeinschaft [PO681/8-1]
  14. Academy of Finland
  15. Canadian Institutes of Health Research [MOP-136839]
  16. MSD (Japan)

向作者/读者索取更多资源

Neuroimaging offers a wide range of opportunities to obtain information about neuronal activity, brain inflammation, blood-brain barrier alterations, and various molecular alterations during epileptogenesis or for the prediction of pharmacoresponsiveness as well as postoperative outcome. Imaging biomarkers were examined during the XIII Workshop on Neurobiology of Epilepsy (XIII WONOEP) organized in 2015 by the Neurobiology Commission of the International League Against Epilepsy (ILAE). Here we present an extended summary of the discussed issues and provide an overview of the current state of knowledge regarding the biomarker potential of different neuroimaging approaches for epilepsy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据